Story
Aqua Capital Boosts Energizer Stake, Betting on 37% Valuation Gap

Summary
Investment firm Aqua Capital has steadily increased its holdings in Energizer, signaling conviction that the battery maker's stock is significantly undervalued despite market concerns over its debt load.
Investment firm Aqua Capital has spent over $6 million on open-market purchases of Energizer Holdings (NYSE:ENR) shares since mid-April, according to a review of market data. The accumulation signals a strong conviction that the battery maker is materially mispriced as its stock trades near the $20 level.
Consistent Accumulation Signals Conviction
Aqua Capital, along with affiliated entities like Durango Capital, has been a consistent buyer of Energizer stock, acquiring at least 460,000 shares since April 14, 2026. The purchases, made at prices ranging from $16.18 to $21.54, have increased the firm's direct stake to approximately 7.48 million shares, valued at around $154 million.
This persistent buying across various price points suggests the firm sees a fundamental valuation gap rather than a short-term trading opportunity. The stock was trading at $20.36 in pre-market activity on Tuesday, a level that one valuation model suggests is significantly below its intrinsic worth.
A Tale of Two Valuations
The bull case for Energizer centers on a disconnect between its stock price and its underlying financial metrics. According to data from GuruFocus, the stock’s intrinsic GF Value is estimated at $31.79 per share, implying a 37% discount from its current price. However, the service also classifies the stock as a 'Possible Value Trap / Contrarian,' highlighting potential risks.
Several metrics point to undervaluation:
Ad- Forward P/E Ratio: Approximately 5.40, a level considered low relative to consumer staples peers.
- Price-to-Sales Ratio: Sits near 0.47 on annualized revenue of roughly $2.95 billion.
- Return on Equity: A notable 144.22%, indicating strong capital efficiency.
The primary concern for investors is Energizer's leveraged balance sheet, which features a high debt-to-equity ratio of 19.08, largely a remnant of acquisitions made in 2019. This has suppressed the stock's valuation multiple, a situation exacerbated by a 23.86% single-day price collapse in November 2025 following a quarterly earnings miss.
Catalysts and Market Outlook
In its fiscal second-quarter 2026 report, Energizer delivered a mixed result that captured its current dynamic. The company posted earnings per share of $0.94, doubling the consensus estimate of $0.47. However, revenue of $643.3 million missed forecasts by 3.15%, and the market focused on the top-line miss, sending shares down 1.91% on the day.
Wall Street's consensus 12-month price target for Energizer is $20.67, with a range spanning from $18 to $28. The stock has recently stabilized near its 50-day and 200-day moving averages, suggesting the prior downtrend may have concluded. Investors are now looking ahead to the company's fiscal third-quarter earnings report, scheduled for August 10, 2026, as the next potential catalyst.
Read next
More on Stocks
Apple's Tim Cook Views Australia's Social Media Curbs as 'World-Leading,' PM Albanese Says
Apple Executive Chair Tim Cook praised Australia's pioneering online safety measures as "world-leading," according to Prime Minister Anthony Albanese following a meeting at the tech giant's California headquarters.

Venezuela's Interim Government Signs Energy MOU with TotalEnergies
Venezuela's interim government signed a memorandum of understanding with French energy major TotalEnergies, the latest in a series of deals aimed at attracting foreign investment back into the nation's vast oil sector.

Huawei Unveils Advanced Power and Cooling Solutions for AI Data Centers
Huawei has launched a new suite of energy infrastructure and thermal management products for AI data centers, signaling a strategic shift towards integrated power storage and intelligent liquid cooling systems to meet the demands of high-density computing.

Shenzhen-Listed Jingxin Pharmaceutical Refiles for Hong Kong IPO
Zhejiang Jingxin Pharmaceutical Co., Ltd. (002020.SZ) has resubmitted its application for a main board listing on the Hong Kong Stock Exchange, aiming to secure a dual listing to access international capital. The company specializes in drugs for central nervous system and cardiovascular diseases.